Hansa names Maria Tornsen to lead US business

13 May 2025

Swedish biotech Hansa Biopharma (Nasdaq Stockholm: HNSA) has appointed Maria Törnsén as chief operating officer and president US, strengthening its commercial leadership ahead of key milestones for its kidney transplant drug Idefirix (imlifidase).

Ms Törnsén previously held senior commercial roles at Calliditas Therapeutics, Sarepta Therapeutics (Nasdaq: SRPT), Sanofi (Euronext: SAN) and Shire, and oversaw US commercial operations during Calliditas’ acquisition by Asahi Kasei in 2024. Her track record includes launching multiple products and leading a $1.6 billion franchise.

Chief executive Renée Aguiar-Lucander said her experience will be “critical” as Hansa scales its commercial operations and navigates the rare disease space.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK